Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y
EXCLI J. 2025; 24:113-150.
PMID: 39967906
PMC: 11830918.
DOI: 10.17179/excli2024-7935.
Shen J, Ding Y
Mol Med Rep. 2025; 31(3).
PMID: 39886962
PMC: 11795254.
DOI: 10.3892/mmr.2025.13441.
Yang H, Xiong R, Zhang R, Sun S, Pan Y, Zhao Q
Mol Carcinog. 2025; 64(4):756-768.
PMID: 39835575
PMC: 11890417.
DOI: 10.1002/mc.23885.
Liu X, Guo H, Kang M, Fu W, Li H, Ji H
Arch Toxicol. 2024; 99(1):299-307.
PMID: 39322821
DOI: 10.1007/s00204-024-03881-5.
Yan Q, Wong W, Gong L, Yang J, Liang D, Chin K
Int J Mol Med. 2024; 54(2).
PMID: 38963019
PMC: 11232667.
DOI: 10.3892/ijmm.2024.5396.
Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.
Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref A, Aljabali A
Cell Mol Life Sci. 2024; 81(1):214.
PMID: 38733529
PMC: 11088560.
DOI: 10.1007/s00018-024-05236-w.
N-methyladenosine-modified VGLL1 promotes ovarian cancer metastasis through high-mobility group AT-hook 1/Wnt/β-catenin signaling.
Li H, Cai L, Pan Q, Jiang X, Zhao J, Xiang T
iScience. 2024; 27(3):109245.
PMID: 38439973
PMC: 10910247.
DOI: 10.1016/j.isci.2024.109245.
TMEM44-AS1 promotes esophageal squamous cell carcinoma progression by regulating the IGF2BP2-GPX4 axis in modulating ferroptosis.
Yang R, Wan J, Ma L, Zhou F, Yang Z, Li Z
Cell Death Discov. 2023; 9(1):431.
PMID: 38040698
PMC: 10692126.
DOI: 10.1038/s41420-023-01727-0.
LINC01305 recruits basonuclin 1 to act on G-protein pathway suppressor 1 to promote esophageal squamous cell carcinoma.
Xiong L, Tan J, Zhang R, Long Q, Xiong R, Liu Y
Cancer Sci. 2023; 114(11):4314-4328.
PMID: 37705202
PMC: 10637064.
DOI: 10.1111/cas.15963.
IGF2BPs as novel mA readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment.
Duan M, Liu H, Xu S, Yang Z, Zhang F, Wang G
Genes Dis. 2023; 11(2):890-920.
PMID: 37692485
PMC: 10491980.
DOI: 10.1016/j.gendis.2023.06.017.
Targeting IGF2BP3 in Cancer.
Liu X, Chen J, Chen W, Xu Y, Shen Y, Xu X
Int J Mol Sci. 2023; 24(11).
PMID: 37298373
PMC: 10253605.
DOI: 10.3390/ijms24119423.
ACSM3 suppresses proliferation and induces apoptosis and cell cycle arrest in acute myeloid leukemia cells via the regulation of IGF2BP2.
Zheng X, Wu J, Song L, Huang B
Exp Ther Med. 2023; 25(4):177.
PMID: 37006876
PMC: 10061044.
DOI: 10.3892/etm.2023.11876.
Long non-coding RNA HOXC-AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression.
Yang Z, Wan J, Ma L, Li Z, Yang R, Yang H
J Clin Lab Anal. 2022; 37(1):e24801.
PMID: 36510377
PMC: 9833966.
DOI: 10.1002/jcla.24801.
CircRNA AFF4 induced by KDM1A promotes osteogenic differentiation through FNDC5/Irisin pathway.
Liu A, Chen Y, Zhong D, Wang C, Yu M, Liu C
Mol Med. 2022; 28(1):134.
PMID: 36401176
PMC: 9673395.
DOI: 10.1186/s10020-022-00557-7.
Potential prognostic value of a eight ferroptosis-related lncRNAs model and the correlative immune activity in oral squamous cell carcinoma.
Qiu L, Tao A, Liu F, Ge X, Li C
BMC Genom Data. 2022; 23(1):80.
PMID: 36384476
PMC: 9667687.
DOI: 10.1186/s12863-022-01097-z.
The Role of mA Modification and mA Regulators in Esophageal Cancer.
Li Y, Niu C, Wang N, Huang X, Cao S, Cui S
Cancers (Basel). 2022; 14(20).
PMID: 36291923
PMC: 9600289.
DOI: 10.3390/cancers14205139.
Role of IGF2BPs in head and neck squamous cell carcinoma.
Wu K, Chang F, Li W, Su T, Lei D
Front Oncol. 2022; 12:1003808.
PMID: 36237306
PMC: 9552850.
DOI: 10.3389/fonc.2022.1003808.
Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X, Zhou L, Gao M, Dong S, Hu Y, Hu C
Front Genet. 2022; 13:989646.
PMID: 36204323
PMC: 9530991.
DOI: 10.3389/fgene.2022.989646.
Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis.
Liu X, Liu C, Zeng J, Zeng D, Chen Y, Tan F
Front Pharmacol. 2022; 13:1010879.
PMID: 36188614
PMC: 9515486.
DOI: 10.3389/fphar.2022.1010879.
Role of m6A writers, erasers and readers in cancer.
Fang Z, Mei W, Qu C, Lu J, Shang L, Cao F
Exp Hematol Oncol. 2022; 11(1):45.
PMID: 35945641
PMC: 9361621.
DOI: 10.1186/s40164-022-00298-7.